Dopamine D2Rs coordinate cue-evoked changes in striatal acetylcholine levels. 2022

Kelly M Martyniuk, and Arturo Torres-Herraez, and Daniel C Lowes, and Marcelo Rubinstein, and Marie A Labouesse, and Christoph Kellendonk
Department of Neuroscience, Columbia University, New York, United States.

In the striatum, acetylcholine (ACh) neuron activity is modulated co-incident with dopamine (DA) release in response to unpredicted rewards and reward-predicting cues and both neuromodulators are thought to regulate each other. While this co-regulation has been studied using stimulation studies, the existence of this mutual regulation in vivo during natural behavior is still largely unexplored. One long-standing controversy has been whether striatal DA is responsible for the induction of the cholinergic pause or whether DA D2 receptors (D2Rs) modulate a pause that is induced by other mechanisms. Here, we used genetically encoded sensors in combination with pharmacological and genetic inactivation of D2Rs from cholinergic interneurons (CINs) to simultaneously measure ACh and DA levels after CIN D2R inactivation in mice. We found that CIN D2Rs are not necessary for the initiation of cue-induced decrease in ACh levels. Rather, they prolong the duration of the decrease and inhibit ACh rebound levels. Notably, the change in cue-evoked ACh levels is not associated with altered cue-evoked DA release. Moreover, D2R inactivation strongly decreased the temporal correlation between DA and ACh signals not only at cue presentation but also during the intertrial interval pointing to a general mechanism by which D2Rs coordinate both signals. At the behavioral level D2R antagonism increased the latency to lever press, which was not observed in CIN-selective D2R knock out mice. Press latency correlated with the cue-evoked decrease in ACh levels and artificial inhibition of CINs revealed that longer inhibition shortens the latency to press compared to shorter inhibition. This supports a role of the ACh signal and it's regulation by D2Rs in the motivation to initiate actions.

UI MeSH Term Description Entries
D003342 Corpus Striatum Striped GRAY MATTER and WHITE MATTER consisting of the NEOSTRIATUM and paleostriatum (GLOBUS PALLIDUS). It is located in front of and lateral to the THALAMUS in each cerebral hemisphere. The gray substance is made up of the CAUDATE NUCLEUS and the lentiform nucleus (the latter consisting of the GLOBUS PALLIDUS and PUTAMEN). The WHITE MATTER is the INTERNAL CAPSULE. Lenticular Nucleus,Lentiform Nucleus,Lentiform Nuclei,Nucleus Lentiformis,Lentiformis, Nucleus,Nuclei, Lentiform,Nucleus, Lenticular,Nucleus, Lentiform,Striatum, Corpus
D003463 Cues Signals for an action; that specific portion of a perceptual field or pattern of stimuli to which a subject has learned to respond. Cue
D004298 Dopamine One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action. Hydroxytyramine,3,4-Dihydroxyphenethylamine,4-(2-Aminoethyl)-1,2-benzenediol,Dopamine Hydrochloride,Intropin,3,4 Dihydroxyphenethylamine,Hydrochloride, Dopamine
D000109 Acetylcholine A neurotransmitter found at neuromuscular junctions, autonomic ganglia, parasympathetic effector junctions, a subset of sympathetic effector junctions, and at many sites in the central nervous system. 2-(Acetyloxy)-N,N,N-trimethylethanaminium,Acetilcolina Cusi,Acetylcholine Bromide,Acetylcholine Chloride,Acetylcholine Fluoride,Acetylcholine Hydroxide,Acetylcholine Iodide,Acetylcholine L-Tartrate,Acetylcholine Perchlorate,Acetylcholine Picrate,Acetylcholine Picrate (1:1),Acetylcholine Sulfate (1:1),Bromoacetylcholine,Chloroacetylcholine,Miochol,Acetylcholine L Tartrate,Bromide, Acetylcholine,Cusi, Acetilcolina,Fluoride, Acetylcholine,Hydroxide, Acetylcholine,Iodide, Acetylcholine,L-Tartrate, Acetylcholine,Perchlorate, Acetylcholine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D017448 Receptors, Dopamine D2 A subfamily of G-PROTEIN-COUPLED RECEPTORS that bind the neurotransmitter DOPAMINE and modulate its effects. D2-class receptor genes contain INTRONS, and the receptors inhibit ADENYLYL CYCLASES. Dopamine D2 Receptors,Dopamine-D2 Receptor,D2 Receptors, Dopamine,Dopamine D2 Receptor,Receptor, Dopamine-D2
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus
D018678 Cholinergic Agents Any drug used for its actions on cholinergic systems. Included here are agonists and antagonists, drugs that affect the life cycle of ACETYLCHOLINE, and drugs that affect the survival of cholinergic neurons. The term cholinergic agents is sometimes still used in the narrower sense of MUSCARINIC AGONISTS, although most modern texts discourage that usage. Acetylcholine Agent,Acetylcholine Agents,Cholinergic,Cholinergic Agent,Cholinergic Drug,Cholinomimetic,Cholinomimetics,Muscarinic,Muscarinic Agent,Muscarinic Agents,Nicotinic Agent,Nicotinic Agents,Cholinergic Drugs,Cholinergic Effect,Cholinergic Effects,Cholinergics,Muscarinic Effect,Muscarinic Effects,Muscarinics,Nicotinic Effect,Nicotinic Effects,Agent, Acetylcholine,Agent, Cholinergic,Agent, Muscarinic,Agent, Nicotinic,Agents, Acetylcholine,Agents, Cholinergic,Agents, Muscarinic,Agents, Nicotinic,Drug, Cholinergic,Drugs, Cholinergic,Effect, Cholinergic,Effect, Muscarinic,Effect, Nicotinic,Effects, Cholinergic,Effects, Muscarinic,Effects, Nicotinic

Related Publications

Kelly M Martyniuk, and Arturo Torres-Herraez, and Daniel C Lowes, and Marcelo Rubinstein, and Marie A Labouesse, and Christoph Kellendonk
January 1979, Communications in psychopharmacology,
Kelly M Martyniuk, and Arturo Torres-Herraez, and Daniel C Lowes, and Marcelo Rubinstein, and Marie A Labouesse, and Christoph Kellendonk
November 1974, Biochemical pharmacology,
Kelly M Martyniuk, and Arturo Torres-Herraez, and Daniel C Lowes, and Marcelo Rubinstein, and Marie A Labouesse, and Christoph Kellendonk
November 1978, The Journal of pharmacy and pharmacology,
Kelly M Martyniuk, and Arturo Torres-Herraez, and Daniel C Lowes, and Marcelo Rubinstein, and Marie A Labouesse, and Christoph Kellendonk
April 1993, European journal of pharmacology,
Kelly M Martyniuk, and Arturo Torres-Herraez, and Daniel C Lowes, and Marcelo Rubinstein, and Marie A Labouesse, and Christoph Kellendonk
April 1974, Life sciences,
Kelly M Martyniuk, and Arturo Torres-Herraez, and Daniel C Lowes, and Marcelo Rubinstein, and Marie A Labouesse, and Christoph Kellendonk
May 1977, Brain research,
Kelly M Martyniuk, and Arturo Torres-Herraez, and Daniel C Lowes, and Marcelo Rubinstein, and Marie A Labouesse, and Christoph Kellendonk
April 2020, Neuron,
Kelly M Martyniuk, and Arturo Torres-Herraez, and Daniel C Lowes, and Marcelo Rubinstein, and Marie A Labouesse, and Christoph Kellendonk
January 2007, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,
Kelly M Martyniuk, and Arturo Torres-Herraez, and Daniel C Lowes, and Marcelo Rubinstein, and Marie A Labouesse, and Christoph Kellendonk
January 1989, Neuroscience letters,
Kelly M Martyniuk, and Arturo Torres-Herraez, and Daniel C Lowes, and Marcelo Rubinstein, and Marie A Labouesse, and Christoph Kellendonk
February 1997, Brain research,
Copied contents to your clipboard!